glp-1 drugs stocks Record Numbers of Americans Are on Drugs. That's Great News for This Stock Eli Lilly stock soars on

Healthcare providers should consider individual patient factors, including baseline kidney function, hydration status, and overall medication regimen

Appetite suppression weakens

& Bankir, L

In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Dulaglutide (Brand name: Trulicity) Administered as a weekly injection, primarily for diabetes